ClinicalTrials.gg
CompletedNCT07827534FdsVC-WAST-uUpdated Sep 18, 2026

Feasibility of Systematic Domestic Violence Screening Using WAST in the Villefranche/Saône Emergency Department.

An observational study in Violence Against Women (VAW), sponsored by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Study summary

This single-center observational study aims to assess the feasibility of systematically screening for intimate partner violence (IPV) against women in the emergency department of Hôpital Nord-Ouest de Villefranche-sur-Saône. The study utilizes the Woman Abuse Screening Tool (WAST), a self-administered questionnaire, to identify cases of IPV. The primary objective is to evaluate the feasibility and acceptability of implementing this systematic screening within an emergency setting. The study will measure feasibility through factors such as the implementation rate and adherence by healthcare staff, while acceptability will be assessed based on patient participation and response rates. By analyzing these criteria, the study seeks to determine whether IPV screening can be effectively integrated into routine emergency care. The findings are expected to provide insights into potential barriers and facilitators for screening implementation, contributing to improved detection and support strategies for women experiencing domestic violence.

02

Conditions studied

  • Violence Against Women (VAW)

Keywords

  • Patient Acceptability
  • Woman Abuse Screening Tool (WAST)
  • Screening Feasibility
  • Intimate Partner Violence (IPV)
  • Violence Against Women (VAW)
03

In context

Lead sponsor

L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult female patients presenting spontaneously to the Emergency Department of Villefranche-sur-Saône Hospital who meet all inclusion criteria and none of the exclusion criteria. The required sample size is estimated at 101 participants.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female
  2. Aged 18 years or older
  3. Able to read and write French

Exclusion criteria

Exclusion Criteria:

  1. Refusal to participate in the study
  2. Neurocognitive disorders, confusion, or psychotic disorders that preclude study participation
  3. Severe uncorrected sensory impairment
  4. Life-threatening emergency requiring immediate management in the resuscitation area
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No

Interventions

  • OtherSelf-questionnaire

    Self-questionnaire completed in the waiting room of the emergency department, either on paper or online by scanning a QR-code

06

What researchers measure

Primary outcomes

  1. Feasibility of systematic screening using WAST

    Assessed by the proportion of eligible women screened with WAST.

    Time frame: At the time of outpatient consultation (Day 0)

  2. Acceptability of WAST

    Assessed using an acceptability questionnaire completed by healthcare patient

    Time frame: At the time of outpatient consultation (Day 0)

07

Study locations

1 site
  • Hopitaux Nord-Ouest
    Gleizé, France 69400, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jun 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
Sep 18, 2026
StartActual
Apr 7, 2025
Primary completionActual
Jun 1, 2025
CompletionActual
Jun 1, 2025
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07827534
Lead sponsor
L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Apr 7, 2025
Primary completion
Jun 1, 2025
Completion
Jun 1, 2025
Last update
Sep 18, 2026

Study contacts

LUCIE TEYSSIER, GENERAL MEDECINE
study chair

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion